Reviews on covid drug development

Aus coViki
Wechseln zu: Navigation, Suche
Candidate Compounds Covid19

32226821 2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
32292689 ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
32318328 ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19
32152082 2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
32232214 2020. Potential Treatments for COVID-19; a Narrative Literature Review
32134278 2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)
32375268 2020. Coronavirus Pandemic-Therapy and Vaccines
31996494 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV)
32334062 ä. Current status of potential therapeutic candidates for the COVID-19 crisis
32347359 ä. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19
32504168 2020. Impact of glycoscience in fighting Covid-19.
32197324 2020. A Review on Applications of Computational Methods in Drug Screening and Design
32387389 2020. Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)
32387332 ä. Current development of COVID-19 diagnostics, vaccines and therapeutics

32387301 2020. The CoV-2 outbreak: how hematologists could help to fight Covid-19
idiotic title; reviews many immunopharmocological targets

32194980 2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
32149769 ä. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
32353634 2020. COVID-19: Immunology and treatment options
32280433 ä. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
32337328 2020. Coronaviruses: A patent dataset report for research and development (R&D) analysis
32309622 ä. Emerging Therapeutic Strategies for COVID-19 patients
32336723 2020. Treatment of SARS-CoV-2: How far have we reached?
32147628 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19)
32198066 ä. Advance of promising targets and agents against COVID-19 in China
32320852 ä. Deja vu: Stimulating open drug discovery for SARS-CoV-2
32304645 ä. Boosting the arsenal against COVID-19 through computational drug repurposing

32343658 2020. Medication for COVID-19-an Overview of Approaches Currently Under Study
32363880 2020. Medical treatment options for COVID-19
32372695 2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol

32250170 2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19?

32317408 2020. Perspectives for repurposing drugs for the coronavirus disease 2019
32317405 2020. Tracking the impact of interventions against COVID-19 in absence of extensive testing
32201449 2020. Drug targets for corona virus: A systematic review
32320825 ä. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
32335561 2020. Update on treatment of COVID-19: ongoing studies between promising and disappointing results
32311668 ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment
32278811 ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19
32272396 ä. The Possible of Immunotherapy for COVID-19: a Systematic Review
32251732 ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage
32305589 ä. Combating Devastating COVID -19 by Drug Repurposing
32325767 2020. COVID-19 Drug Discovery Using Intensive Approaches
32234466 ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives
32255648 ä. A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19
32315171 ä. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
32243270 2020. Potential therapeutic agents against COVID-19: What we know so far
32314081 ä. Pharmacologic Therapy for COVID-19 Infection
32326602 2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19
32307245 ä. Treatment options for COVID-19: The reality and challenges
32251618 2020. Current Drugs with Potential for Treatment of COVID-19: A Literature Review
32361836 ä. CNS penetration of potential anti-COVID-19 drugs
32374264 2020. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point
32321634 2020. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome
32186952 2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
32341599 2020. Is Immuno-modulation the Key to COVID-19 Pandemic?
32293807 2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment
32356252 ä. COVID-19: Therapeutics and Their Toxicities
32052466 2020. Potential interventions for novel coronavirus in China: A systematic review
32346490 ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
32035018 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option
32317113 2020. COVID-19 therapeutic options for patients with kidney disease
32220278 2020. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
32305088 2020. Flooded by the torrent: the COVID-19 drug pipeline
32199468 ä. Use of antiviral drugs to reduce COVID-19 transmission
32325035 ä. Plea for multitargeted interventions for severe COVID-19
32113509 2020. COVID-19: combining antiviral and anti-inflammatory treatments
32368737 2020. Preventing COVID-19-induced pneumonia with anticytokine therapy
32278693 2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
32198163 2020. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
32292909 2020. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies
32370766 2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines

32231348 2020. Emerging prophylaxis strategies against COVID-19
32296135 ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
32284951 2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
32369479 2020. Antibody-based therapies for COVID-19: Can Europe move faster?
32360583 ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis
32343686 2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks
32360480 ä. Candidate drugs against SARS-CoV-2 and COVID-19
32290348 2020. COVID-19: A Brief Overview of the Discovery Clinical Trial
32360585 ä. Current targeted therapeutics against COVID-19: based on first-line experience in china
32098302 2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development
32256547 2020. Clinical trials on drug repositioning for COVID-19 treatment
32333199 ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19
32313660 2020. A short review on antibody therapy for COVID-19
C7110269 ä. COVID-19 Outbreak: an Update on Therapeutic Options
32124179 ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need
32334088 ä. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
32278175 ä. COVID-19: A promising cure for the global panic
32293834 2020. Antiviral treatment of COVID-19
32371057 ä. Potential applications of plant biotechnology against SARS-CoV-2
32291112 ä. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
32287799 2020. Drug trials under way
32187463 ä. Covid-19 ? The Search for Effective Therapy
32274985 2020. Novel Coronavirus Disease (COVID-19): The Need for Immunoprevention at Industrial Scale
32354113 2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges
32326343 2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?
32213152 2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?

32376392 ä. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

32217607 2020. Covid-19: what treatments are being investigated?
32304110 2020. Dosing will be a key success factor in repurposing antivirals for COVID-19
32356569 2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology
32368792 2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2

32358833 2020. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development IUPHAR Review 29

32329520 2020. Current pharmacological treatments for COVID-19: What s next?
32371479 2020. Cytokine Storm Drugs Move from CAR T to COVID-19
32303509 2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19
32344310 2020. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality

32324951 2020. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics

32366720 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
32209549 2020. Covid-19: trials of four potential treatments to generate "robust data" of what works
32205349 2020. Updated Approaches against SARS-CoV-2

32376394 ä. Immunomodulatory therapy for the management of severe COVID-19 Beyond the anti-viral therapy: A comprehensive review
32376397 ä. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view

32329159 2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach
32277367 ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets
32345616 2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19
32304395 2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support
32203437 ä. Insights from nanomedicine into chloroquine efficacy against COVID-19
32360420 ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia
32272550 2020. Antiviral Agents: Discovery to Resistance
32268515 2020. In Silico Discovery of Candidate Drugs against Covid-19
32357553 2020. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19
32117569 2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
32295237 2020. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs
32133962 2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China
32373994 2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope
32362193 2020. Quadruple therapy for asymptomatic COVID-19 infection patients
32227357 ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight
32377559 ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
32306822 2020. Peptide-like and small-molecule inhibitors against Covid-19
32317431 2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
32370727 2020. SARS-CoV-2 & Covid-19: Key-Roles of the Renin-Angiotensin System / Vitamin D Impacting Drug and Vaccine Developments
32281695 2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases
32379896 2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs
32239514 ä. Comments on Zhang et al: Clinical trial analysis of 2019?nCoV therapy registered in China
32157732 ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs
32380023 ä. Immunomodulation in COVID-19
32289216 2020. Drug Evaluation during the Covid-19 Pandemic
32372435 2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment
32273591 2020. The COVID-19 vaccine development landscape

32378459 2020. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses
32363750 2020. A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL)
32353859 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

32269311 2020. Coordinating the COVID-19 pipeline
32127666 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
32324177 2020. Some drugs for COVID-19
32208486 2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics
32297900 2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis
32282022 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
32216577 2020. Artificial intelligence and machine learning to fight COVID-19
32219882 ä. Controversial treatments: An updated understanding of the coronavirus disease 2019
32297985 2020. Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
32108352 ä. Clinical trial analysis of 2019?nCoV therapy registered in China
32259313 2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
C7187737 ä. COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective
32164080 2020. Potential antiviral therapeutics for 2019 Novel Coronavirus
32164081 2020. Pharmacotherapeutics for the new coronavirus pneumonia
32164077 2020. Pharmacotherapeutic about the new coronavirus pneumonia
C7197606 ä. Antibody therapies for the treatment of COVID-19
32302280 2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
32220178 2020. Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019
32376392 2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
32099652 2020. Frontiers in antiviral therapy and immunotherapy
32243785 2020. Embracing the Landscape of Therapeutics
C7117595 ä. Drug repurposing strategies for COVID-19
32377559 ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
32364041 2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2
C7202831 ä. Testing COVID-19 therapies to prevent progression of mild disease
32201439 2020. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach
32105468 2020. Structure-Based Stabilization of Non-native Protein?Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design
32081774 2020. Discovery and development of safe-in-man broad-spectrum antiviral agents
32395606 2020. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study.
28664850 2017. (+)Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome
32389723 2020. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.
32382315 2020. Can graphene take part in the fight against COVID-19?
32313660 2020. A short review on antibody therapy for COVID-19
32317764 ä. Developing therapeutic monoclonal antibodies at pandemic pace
31432544 2020. Repurposing approved drugs on the pathway to novel therapies
32373787 2020. A new paradigm for drug development
32409074 2020. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents
C7190528 ä. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
32382873 2020. Covid-19 and drug therapy, what we learned.
32470577 2020. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.
32526460 2020. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.
32327922 2020. The 4 D's of Pellagra and Progress.
32447429 2020. Trials and tribulations: so many potential treatments, so few answers.
32483523 2020. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
32426222 2020. The Ethics of COVID-19 Clinical Trials: New Considerations in a Controversial Area.
32394467 2020. A global treatments for coronaviruses including COVID-19.
32488835 2020. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.
32493626 2020. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.
32489437 2020. Clinical trials for coronavirus disease 2019: What is being evaluated and what is not.
32350686 2020. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
32454090 2020. The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).
32406904 2020. Clinical trials: management of investigational products during the coronavirus (COVID-19) pandemic.
32478500 2020. COVID-19 and Other Pandemics: How Might They Be Prevented?
32519842 2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.
32405780 2020. Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.
32297590 2020. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
32383582 2020. When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy.
32432466 2020. Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19.
32426387 2020. Artificial intelligence approach fighting COVID-19 with repurposing drugs.
32410772 2020. Emerging pharmacotherapies for COVID-19.
32440566 2020. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19.
32514689 2020. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
32426388 2020. Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor.
32446195 2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.
32508168 2020. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.
32406687 2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.
32454981 2020. Current regulatory approaches for accessing potential COVID-19 therapies.
32525650 2020. Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19?
32385829 2020. COVID-19 and off label use of drugs: an ethical viewpoint.
32515404 2020. Comprehensive overview of COVID-19 clinical trials.
32515383 2020. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.
32418299 2020. The COVID-19 chemoprophylactic conundrum: Are we limiting available resources?

32451923 2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.
32469436 2020. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.

32523611 2020. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic.
32499832 2020. Pharmacological treatment of COVID-19: lights and shadows.
32395418 2020. An Update on Current Therapeutic Drugs Treating COVID-19.
32391242 2020. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.
32525715 2020. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.
32414641 2020. The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed.
32427166 2020. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.
32523109 2020. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.
32476308 2020. Empirical Treatment and Prevention of COVID-19.
32392184 2020. Clinical trials for COVID-19 should include sex as a variable.
32486364 2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.
32293020 2020. Palliativ farmakologisk behandling vid svar covid-19.
32444382 2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
32466136 2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.
32486488 2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.
32486229 2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.
32481690 2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.
32495979 2020. Emergence of novel coronavirus and progress toward treatment and vaccine.
32485102 2020. Current Perspective of Antiviral Strategies against COVID-19.
32369098 2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
32398377 2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.
32501513 2020. How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics.
32433861 2020. How to Discover Antiviral Drugs Quickly.
32515974 2020. Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition.
32486283 2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.
32409452 2020. Pandemic could add noise to clinical trial data.
32395792 2020. COVID-19: Main therapeutic options.
32423024 2020. The Rationale for Potential Pharmacotherapy of COVID-19.
32434254 2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.
32381590 2020. Ethics of controlled human infection to address COVID-19.
32527823 2020. Aggregating data from COVID-19 trials.
32518636 2020. A snapshot of the ongoing clinical research on COVID-19.
32395702 2020. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?
32390971 2020. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.
32426374 2020. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.
32057209 2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].
32433189 2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.
32391659 2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].

32473596 2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

32496239 2020. Potential pharmacological agents for COVID-19.
32490731 2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.
32502901 2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.
32492205 2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.
32427277 2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
32421836 2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.
32420637 2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.

32438473 2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.

32381697 2020. The race is on for antibodies that stop the new coronavirus.
32381692 2020. Combination prevention for COVID-19.
32461212 2020. Reducing transmission of SARS-CoV-2.
32385101 2020. Rapid repurposing of drugs for COVID-19.
32327575 2020. NIH organizes hunt for drugs.
32448085 2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
32469418 2020. Evaluation of potential therapeutic options for COVID-19.
32409433 2020. Antivirals for COVID-19.
32458475 2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.
32428941 2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.
32437001 2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".
32449669 2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.
32472779 2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?
32508069 2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.
32324361 2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]
32503817 2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
32282262 2020. Treatment considerations for coronavirus (COVID-19).
32469280 2020. COVID-19: Gene Transfer to the Rescue?
32423245 2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.
32212981 2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.
32427004 2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?
32452701 2020. An up-to-date overview of computational polypharmacology in modern drug discovery.
32468014 2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).
32447996 2020. Treatments in the COVID-19 pandemic: an update on clinical trials.
32398330 2020. A Call for Pediatric COVID-19 Clinical Trials.
32423342 2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?
32393419 2020. Recent advances of therapeutic targets and potential drugs of COVID-19.
32325475 2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.
32434272 2020. COVID-19Clinical trials: quality matters more than quantity.
32364561 2020. Randomized Clinical Trials and COVID-19: Managing Expectations.
32463427 2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.
32504019 2020. The coronavirus outbreak could make it quicker and easier to trial drugs.

32424192 2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
32415276 2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.
32409766 2020. Dozens of coronavirus drugs are in development - what happens next?
32405023 2020. Coronavirus drugs trials must get bigger and more collaborative.
32462996 2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.
32393915 2020. Biggest COVID-19 trial tests repurposed drugs first.
32417850 2020. Drug researchers pursue new lines of attack against COVID-19.
32415300 2020. Biotech companies prepare for COVID-19 downturn.
32415251 2020. 15 drugs being tested to treat COVID-19 and how they would work.
32433345 2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.

32476574 2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.
32505821 2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.

32267762 2020. Research towards treating COVID-19.
32220033 2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).
32424836 2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
32511912 2020. COVID-19: Drug targets and potential treatments.
32441462 2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.
32445484 2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.
32438446 2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
32510105 2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.

32418327 2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.
32407491 2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.

32420936 2020. Treatments for COVID-19: emerging drugs against the coronavirus.
32425152 2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
32506621 2020. Drugs being investigated for children with COVID-19.
32345591 2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.
32423954 2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.
32459832 2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.
32503806 2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.
32474583 2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.
32498751 2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.
32282303 2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
32428965 2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.
32419517 2020. Emerging therapies for COVID-19 pneumonia.
32429703 2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
32419524 2020. Old and re-purposed drugs for the treatment of COVID-19.
32223349 2020. How could artificial intelligence aid in the fight against coronavirus?

32340978 2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.
32500928 2020. COVID-19 breakthroughs: separating fact from fiction.
32212378 2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.
32518135 2020. Paediatric treatment trials for COVID-19 are an ethical imperative.
32284037 2020. Perspective on the COVID-19 Coronavirus Outbreak.
32174284 2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.
32400323 2020. In vitro data of current therapies for SARS-CoV-2.
32427000 2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.
32515023 2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.
32514859 2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.
32378805 2020. COVID-19 and toxicity from potential treatments: Panacea or poison.

32398976 2020. siRNA could be a potential therapy for COVID-19.

32416679 2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
32394841 2020. COVID-19: An Update on Clinical Trials.
32498131 2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.
32509284 2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.
32350861 2020. COVID-19: A Defining Moment for Clinical Pharmacology?
32501511 2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
32405423 2020. Minimum costs to manufacture new treatments for COVID-19.
32294756 2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.
32410758 2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.
32534175 2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.
32535080 2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
32497632 2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
32462988 2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).
32399095 2020. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2.
32505072 2020. COVID-19 and picotechnology: Potential opportunities.
32430617 2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).
32502640 2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak.
32454586 2020. Demand for potentially hazardous COVID-19 treatments.
32454583 2020. ICER releases pricing models for potential COVID-19 treatments.
32473310 2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
32529545 2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?
32531236 2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
32471655 2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.
32454984 2020. Battling COVID-19: using old weapons for a new enemy.
32436445 2020. Potential specific therapies in COVID-19.
32483428 2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.
32467561 2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.

32532085 2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).

32543882 2020. Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy.
32555446 2020. Overview of therapeutic drug research for COVID-19 in China.

32562705 2020. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.

32492407 2020. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.
32586336 2020. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19.

32572376 2020. Literature-based review of the drugs used for the treatment of COVID-19.

32572174 2020. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.
32546835 2020. Immune checkpoint blockade: rele